Pharmaceutical and Medicinal Chemistry

Prof. Dr. Matthias Gehringer

Medizinische Chemie
Medizinische Fakultät
Eberhard Karls Universität Tübingen
Auf der Morgenstelle 8 (Haus B, Raum 8A26)
D - 72076 Tübingen
Tel.: +49 7071 29 74582
Fax: +49 7071 29 5037
E-Mail: matthias.gehringerspam


Matthias studied chemistry at the Karlsruhe Institute of Technology (KIT), the École Nationale Supérieure de Chimie de Montpellier (ENSCM) and the University of Heidelberg, where he graduated in 2008. After completing his master thesis under the supervision of Prof. Christian Klein, he joined BASF SE in Ludwigshafen for a four-month industrial internship, followed by three months of voluntary social work in Tororo, Uganda. He then moved to the University of Tübingen to work in the group of Prof. Stefan Laufer where he primarily focused on protein kinase inhibitors targeting the Janus kinase (JAK) family. In 2014, Matthias obtained his Ph. D. in pharmaceutical/medicinal chemistry with honors (summa cum laude). He joined the lab of Prof. Karl-Heinz Altmann at the Swiss Federal Institute of Technology (ETH) Zürich to pursue postdoctoral research on the total synthesis and biological properties of mycolactones (in cooperation with Prof. Gerd Pluschke, Swiss TPH Basel) and the cell type-specific targeting of antibiotics via­ conjugation to proteins (in cooperation with Prof. Martin Bachmann, Inselspital Bern). He returned to Tübingen in 2017 as a fellow of the Recruitment of Excellent Young Researchers program and was appointed as an Assistant Professor ("W1 Juniorprofessor") at the Institute of Pharmaceutical Sciences at Tübingen University in 2019. In the same year, he became Associate Investigator in the Cluster of Excellence "Image-guided and Functionally Instructed Tumor Therapies (iFIT)". Very recently, he was appointed Full Professor for Medcinal Chemistry at the Faculty of Medicine at the University of Tübingen.

Matthias' research interests include medicinal chemistry and chemical biology as well as drug targeting approaches with current key areas of research being the design of covalent protein kinase inhibitors and the development of novel electrophilic warheads for covalent targeting approaches. Special efforts are directed towards the development of highly selective chemical probes for mapping the untargeted kinome.